Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 1.00 |
| ▸ | ABL1 | P00519 | 5/20 | 0.63 |
| ▸ | BCR | P11274 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107843 | 0.90 | KIF11 (0.82) | KIF11ABL1BCRPGREPHX2 | |
| SCHEMBL3379953 | 0.85 | KIF11 (0.74) | KIF11ABL1BCR | |
| SCHEMBL3375773 | 0.83 | KIF11 (0.70) | KIF11ABL1BCRPGREPHX2 | |
| SCHEMBL28913958 | 0.82 | KIF11 (0.69) | KIF11MAPK1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL3379345 | 0.82 | KIF11 (0.68) | KIF11ABL1BCREPHX2MAPK1 | |
| SCHEMBL3372908 | 0.82 | KIF11 (0.68) | KIF11ABL1BCREPHX2NR1H4 | |
| SCHEMBL3378630 | 0.81 | KIF11 (0.67) | KIF11ABL1BCREPHX2NR1H4 | |
| SCHEMBL937250 | 0.81 | KIF11 (0.65) | KIF11ABL1BCRMAPK1SMN1; SMN2 | |
| SCHEMBL31041151 | 0.80 | KIF11 (0.79) | KIF11PGRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL28575423 | 0.79 | KIF11 (0.65) | KIF11PGRMAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | claimed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | claimed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | claimed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | KIF11 3561/4885ABL1 1571/4885BCR 1316/4885 |
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | KIF11 824/4885ABL1 3323/4885BCR 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.